Search
for
Sort by
Research
390-420 / 1000+ results
research 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
Baricitinib significantly improves hair regrowth in severe alopecia areata.
research ISID1116 – Novel androgen receptor degrader for androgenetic alopecia (AGA) application
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research Drug Discovery Insights from a Computational QSAR Study on Alpha-Reductase Inhibitors and Layered Double Hydroxides Electrocatalysts
Computational techniques can improve drug development for treating certain conditions.
research Dual Relief: How Atopic Dermatitis Treatments Affect Alopecia Areata—A Small Retrospective Cohort Study
Most patients improved in both atopic dermatitis and alopecia areata with certain treatments, but some had worsened symptoms, suggesting personalized care is needed.
research Index
I cannot provide a summary without content from the document.
research Index
I cannot provide a summary without content from the document.
research Index
I cannot provide a conclusion without the content of the document.
research Index
I cannot provide a conclusion without the content of the document.
research Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor
An elderly Chinese man lost all his hair after taking a new heart medication.
research ILDS Newsletter No. 29
The ILDS Newsletter reported on efforts to support albinism patients in Tanzania and dermatological conferences.
research Androgenetic Alopecia
research Androgenetic Alopecia
research Development and pilot-testing of the Alopecia Areata Assessment Tool (ALTO)
The Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata from other hair loss types but needs more validation.
research Index
research Index
research 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.
research ASSESSMENT OF SERUM LEVELS OF ANTIGLIADIN ANTIBODIES (IgG and IgA) IN PATIENTS WITH ALOPECIA AREATA AND THEIR RELATION TO SEVERITY OF THE DISEASE
Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.
research Subject Index, Vol. 7,1994
research 62045 Dermatologist Utilization of Medications Associated with Androgenic Alopecia Treatment Among Medicare Beneficiaries
research Alfuzosin/finasteride
research Alfuzosin/finasteride
research Abstracts Presented at 41st Annual, 9th International Conference of the Islamic Medical Association of North America and First Joint Conference with the Federation of Islamic Medical Associations (FIMA), July 31-August 2, 2008
The document's content cannot be summarized because it is not accessible or understandable.
research Blood Indices in Patients with Androgenetic Alopecia
Higher NLR, PLR, and MPV may help diagnose androgenetic alopecia.
research A study of the Geheimratsacken angle as predictor for early diagnosis of androgenetic alopecia in adolescent population
research Androgenetic Alopecia
research Androgenetic Alopecia
research 76221 Faster Onset and Superior Efficacy of an Investigational Extended-Release Oral Minoxidil Tablet (VDPHL01) Versus Topical and Immediate-Release Oral Minoxidil for Androgenetic Alopecia: Results from a Blinded Retrospective Investigator Global Assessment
research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.